Skip to content

Study · Measured the body's own peptide · 1988

3 results

Isolation and structural characterization of thymosin-beta 4 from a human medullary thyroid carcinoma.

Conlon JM, Grimelius L, Wallin G, Thim L

The Journal of endocrinology1 Jul 1988Cited by 17 (Europe PMC)

PMID3411280 (opens in a new tab)DOI10.1677/joe.0.1180155 (opens in a new tab)PepBankPUB-03411280
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01HumanEndogenous levelCase report or seriesOther

    An extract of a human medullary thyroid carcinoma metastasis contained thymosin beta‑4 at a concentration of at least 2.9 nmol/g wet weight.

    In plain wordsIn one thyroid tumour sample, the body's own thymosin beta‑4 was present at a high concentration.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableThymosin-beta 4 concentration in a medullary thyroid carcinoma metastasis
    Study

    n: not reported in source

    Outcome group
    Endogenous peptide levels · Cancer

    Measurements

    tissue concentration
    ≥ 2.9 nmol/g wet weight
    medullary thyroid carcinoma metastasis

    Source sentences

    Summary
    An extract of a tumour metastases from a human medullary thyroid carcinoma contained a high concentration (at least 2.9 nmol/g wet weight) of the immunoregulatory peptide, thymosin-beta 4.
    1 context sentence
    Title · context
    Isolation and structural characterization of thymosin-beta 4 from a human medullary thyroid carcinoma.

    This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.

Studies that did not test the peptide alone2

In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin beta-4 (human).

  1. 02LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Other

    The peptide was isolated as a mixture of two components with free and blocked NH2-terminal residues, the blocked form predominating at approximately 98%.

    In plain wordsIn lab tests, thymosin beta‑4 from the tumour came as two forms, and almost all had a blocked end.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableFree and blocked NH2-terminal forms of isolated thymosin-beta 4
    Study

    n: not reported in source

    isolated peptide
    Outcome group
    Synthesis and manufacturing · Pharmacology

    Measurements

    blocked form share
    ≈ 98%
    isolated peptide

    Source sentences

    Summary
    The peptide was isolated as a mixture of two components with free and blocked NH2-terminal amino acid residues, the latter form predominating (approximately 98% of the total).
    1 context sentence
    Title · context
    Isolation and structural characterization of thymosin-beta 4 from a human medullary thyroid carcinoma.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

  2. 03LabNot a test of Thymosin beta-4 (human) aloneIn vitro (cell-free)Other

    The amino acid sequence of human thymosin beta‑4 was identical to thymosin beta‑4 previously isolated from calf thymus.

    In plain wordsIn lab tests, human thymosin beta‑4 had the same sequence as thymosin beta‑4 from calf thymus.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    Not applicableAmino acid sequence of tumour thymosin-beta 4
    Study

    n: not reported in source

    Edman degradation sequencing
    Outcome group
    Synthesis and manufacturing · Pharmacology

    Source sentences

    Summary
    The amino acid sequence of human thymosin-beta 4 was identical to thymosin-beta 4 previously isolated from calf thymus.
    1 context sentence
    Title · context
    Isolation and structural characterization of thymosin-beta 4 from a human medullary thyroid carcinoma.

    In this study, Thymosin beta-4 (human) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin beta-4 (human).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 01:52 UTC

    Study results updated

  2. Version 1

    12 Oct 2026, 18:17 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.